[go: up one dir, main page]

NO20060808L - Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom - Google Patents

Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom

Info

Publication number
NO20060808L
NO20060808L NO20060808A NO20060808A NO20060808L NO 20060808 L NO20060808 L NO 20060808L NO 20060808 A NO20060808 A NO 20060808A NO 20060808 A NO20060808 A NO 20060808A NO 20060808 L NO20060808 L NO 20060808L
Authority
NO
Norway
Prior art keywords
treatment
joint disease
pak
pak inhibitor
inhibitor
Prior art date
Application number
NO20060808A
Other languages
English (en)
Inventor
Thomas Leeuw
Ekkehard Leberer
Eckart Bartnik
Joerg Czech
Sebastian Barradeau
Andreas Klatt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20060808L publication Critical patent/NO20060808L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Oppfinnelsen refererer til bruken av p21 -aktivert kinase (PAK) inhibitor for behandling av en leddsykdom, slik som osteoartritt eller reumatoid artritt, eller for behandling av en leddsmerte og bruken a PAK som et målprotein for oppdagelsen av PAK-inhibitor som et medikament for behandling av en leddsykdom
NO20060808A 2003-07-18 2006-02-20 Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom NO20060808L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016303A EP1498133A1 (en) 2003-07-18 2003-07-18 Use of a pak inhibitor for the treatment of a joint disease
PCT/EP2004/007855 WO2005011721A2 (en) 2003-07-18 2004-07-15 Use of a pak inhibitor for the treatment of a joint disease

Publications (1)

Publication Number Publication Date
NO20060808L true NO20060808L (no) 2006-04-12

Family

ID=33462155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060808A NO20060808L (no) 2003-07-18 2006-02-20 Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom

Country Status (13)

Country Link
EP (3) EP1498133A1 (no)
JP (1) JP4843487B2 (no)
KR (2) KR101238755B1 (no)
CN (1) CN1826130B (no)
AU (1) AU2004260590B2 (no)
BR (1) BRPI0412760A (no)
CA (1) CA2532742C (no)
IL (3) IL173145A (no)
MX (1) MXPA06000637A (no)
NO (1) NO20060808L (no)
RU (1) RU2360696C2 (no)
WO (1) WO2005011721A2 (no)
ZA (1) ZA200510377B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP2221385A3 (en) 2005-10-28 2010-12-01 Life Technologies Corporation Deubiquination assays
AU2007208213A1 (en) * 2006-01-24 2007-08-02 University Of Virginia Patent Foundation Compositions and methods for inhibition leukocyte function
KR100835795B1 (ko) * 2006-11-17 2008-06-09 김응국 키나아제 팩2의 활성을 저해하는 펩타이드
CN105169389A (zh) 2008-08-01 2015-12-23 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂
GB0814570D0 (en) * 2008-08-08 2008-09-17 Diagnostics For The Real World Isolation of nucleic acid
WO2010017478A2 (en) * 2008-08-08 2010-02-11 The Board Of Trustees Of The University Of Illinois Pak1 agonists and methods of use
EP3043179B1 (en) * 2009-04-01 2020-05-06 Galapagos N.V. Methods and means for treatment of osteoarthritis
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
WO2011093081A1 (ja) 2010-01-29 2011-08-04 Ａｘｉｓ株式会社 変形性関節症治療剤を含有する注射剤
CA2788527A1 (en) 2010-01-29 2011-08-04 Axis Inc. Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor
US12129308B2 (en) * 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
CN114042053B (zh) * 2021-10-25 2023-07-25 北京理工大学 siRNA输送载体及其制备方法和应用
WO2023097475A1 (zh) * 2021-11-30 2023-06-08 绍兴守仁医疗健康科技有限公司 人pak1蛋白的真核表达载体的构建方法、表达和纯化方法
CN114767864B (zh) * 2022-05-10 2023-05-12 天津医科大学总医院 Pak3抑制剂在治疗瑞芬太尼诱发的切口痛觉过敏中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
CA2174339A1 (en) 1993-10-27 1995-05-04 Lech W. Dudycz 2'-amido and 2'-peptido modified oligonucleotides
US5518911A (en) * 1995-01-06 1996-05-21 Onyx Pharmaceuticals, Inc. Human PAK65
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
HUP9902673A3 (en) 1996-03-25 2001-04-28 Lohmann Therapie Syst Lts Transdermal therapeutic system with small application-area thickness and great flexibility, and production process
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
AU6536698A (en) 1997-02-24 1998-09-09 Tm Technologies, Inc. Anti-sense oligonucleotide pharmacological agents
US6383734B1 (en) * 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
WO2000060062A2 (en) * 1999-04-01 2000-10-12 Astrazeneca Uk Limited Human signal transduction serine/threonine protein kinase

Also Published As

Publication number Publication date
CN1826130A (zh) 2006-08-30
KR20060052832A (ko) 2006-05-19
ZA200510377B (en) 2006-10-25
AU2004260590B2 (en) 2010-06-03
BRPI0412760A (pt) 2006-09-26
IL198727A (en) 2011-03-31
CA2532742C (en) 2013-07-09
JP2007537134A (ja) 2007-12-20
KR101299936B1 (ko) 2013-08-26
KR20120034250A (ko) 2012-04-10
WO2005011721A2 (en) 2005-02-10
EP2275116A1 (en) 2011-01-19
JP4843487B2 (ja) 2011-12-21
RU2006105013A (ru) 2006-06-27
EP1498133A1 (en) 2005-01-19
WO2005011721A3 (en) 2005-04-21
KR101238755B1 (ko) 2013-03-07
CA2532742A1 (en) 2005-02-10
IL173145A (en) 2010-12-30
IL204861A (en) 2011-09-27
AU2004260590A1 (en) 2005-02-10
RU2360696C2 (ru) 2009-07-10
MXPA06000637A (es) 2006-08-23
EP1648486A2 (en) 2006-04-26
HK1096854A1 (en) 2007-06-15
IL173145A0 (en) 2006-06-11
CN1826130B (zh) 2012-08-29

Similar Documents

Publication Publication Date Title
NO20060808L (no) Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
GT200900147A (es) Derivados de pirimidina y los métodos para su uso
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
NO20032831L (no) Pyrimidinaminer som angiogenese-modulatorer
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20092274L (no) Ansamycinformuleringer og fremgangsmater for anvendelse derav
CL2004000778A1 (es) Compuestos derivados de heterociclos de 5 miembros, inhibidores de la porteina tirosina fosfatasa 1b (ptp1b); composiciones farmaceuticas, utiles para tratar hipertension, obesidad, diabetes, hiperlipidemia.
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
SI1536827T1 (sl) Uporaba protein-kinaze n beta
ECSP066411A (es) Tienopirazoles
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
NO20014986L (no) 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
NO20056046L (no) Oralt dispergerbar flerlags tablett
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
ATE438618T1 (de) Inhibitoren von humanem adam-10
MX2025003515A (es) Moduladores de akt1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application